

APR 02 2014

K132021

1.4 510(k) Summary

Submitted by: Phuong Nguyen
Senior Regulatory Affairs Manager
Nobel Biocare USA LLC
22715 Savi Ranch Parkway
Yorba Linda, CA 92887

Submitted for: Nobel Biocare AB
Vastra Hamngatan 1
Goteborg, SE 411 17
Sweden

Telephone: (714) 282-4800 x7830

Facsimile: (714) 998-9348

Date of Submission: November 1, 2013

Classification Name: Endosseous Dental Implant Abutment (21 CFR 872.3630)
Pro Code: NHA

Trade or Proprietary
or Model Name: NobelProcera Angulated Screw Channel Abutment Replace

Legally Marketed Devices: Nobel Biocare – Esthetic Zirconia Abutment (K031719)

Device Description:

Nobel Biocare's NobelProcera Angulated Screw Channel Abutment Replace is an endosseous dental implant abutment. The abutment attaches directly to Nobel Biocare dental implants with a conical connection and provides a platform for restoration.

Nobel Biocare's NobelProcera Angulated Screw Channel Abutment Replace is designed and made individually to fit the individual requirements for each patient. The abutments are a two piece design with an adapter portion made of titanium vanadium alloy and an abutment portion made of zirconium oxide. The screw channel can be angulated between 0° and 25° as required.

Indications for Use:

The NobelProcera Angulated Screw Channel Abutment Replace are premanufactured prosthetic components directly connected to endosseous dental implants and are intended for use as an aid in prosthetic rehabilitation.

Summary of testing to demonstrate safety and effectiveness

Non-clinical test data was used to support the decision of safety and effectiveness. Clinical testing was not necessary. Non-clinical testing consisted of performance of fatigue testing in accordance with the FDA guidance Class II Special Controls Guidance Document: Root-form Endosseous Dental Implants and Endosseous Dental Implant Abutments.

Comparison of Technological Characteristics

ATTRIBUTE	CANDIDATE	PREDICATE
	NobelProcera Angulated Screw Channel Abutment Replace	Esthetic Zirconia Abutment (K031719)
Design/ construction	Patient specific / machined	Patient specific / machined
Anatomical Site	Oral Cavity	Oral Cavity
Platform compatibility	Nobel Biocare - Replace	Nobel Biocare - Branemark - Replace
Screw Channel	Variable 0° to 25°	Fixed 0°
Device Material	Implant Adapter - Titanium/vanadium alloy Abutment Body - Zirconium oxide	Zirconium oxide
Indications for Use	The NobelProcera Angulated Screw Channel Abutment Replace are premanufactured prosthetic components directly connected to endosseous dental implants and are intended for use as an aid in prosthetic rehabilitation.	Nobel Biocare's Esthetic Zirconia Abutment is indicated for the treatment of partially edentulous patients requiring prosthetic devices and/or endosseous implants to restore chewing function.

Conclusion

The information provided in this submission demonstrates that the device is substantially equivalent to the predicate device.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

April 2, 2014

Allied Healthcare
C/O Mr. John Smith
Partner
555 Thirteenth Street NW
WASHINGTON D.C. 20004

Re: K132021

Trade/Device Name: AHP300 Emergency Portable Ventilator
Regulation Number: 21 CFR 868.5925
Regulation Name: Powered Emergency Ventilator
Regulatory Class: II
Product Code: BTL
Dated: March 5, 2014
Received: March 5, 2014

Dear Mr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Digitally signed by
Richard C. Chapman
Date: 2014.04.02
16:46:56 -04'00'

for

Erin I. Keith, M.S.
Acting Director
Division of Anesthesiology, General Hospital,
Respiratory, Infection Control and
Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K132021

Device Name
AHP300 Emergency Portable Ventilator

Indications for Use (Describe)

The AHP300 (with internal compressor) is intended to be used as an electrically controlled emergency ventilator. This ventilator is designed to provide emergency respiratory support by means of a face mask or tube inserted into the patient's airway. The ventilator is intended for use on patients weighing greater than 5kg (11 lbs). The ventilator is intended to be used in the environments associated with emergency medical services (EMS), inter-hospital transport and hospital facilities usage by qualified, trained personnel under the direction of a physician. The ventilator is intended to be used in temperatures of -18 C to 50 C (0 F to 122 F) and 5% to 95% relative humidity non-condensing.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)



Digitally signed by
Richard C. Chapman
Date: 2014.04.02
16:35:09 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."